Find in Library

Ticagrelor is a powerful P2Y₁₂ inhibitor with pleiotropic effects in the cardiovascular system. Consistently, we have reported that in patients with stable coronary artery disease (CAD) and concomitant chronic obstructive pulmonary disease (COPD) who underwent percutaneous coronary intervention (PCI), 1-month treatment with ticagrelor was superior in improving biological markers of endothelial function, compared with clopidogrel. The objective of this study was to investigate the mechanisms underlying these beneficial effects of ticagrelor by conducting molecular analyses of RNA isolated from peripheral blood cells of these patients. We determined mRNAs levels of markers of inflammation and oxidative stress, such as <i>ROR&#947;t</i> (T helper 17 cells marker), <i>FoxP3</i> (regulatory T cells marker), <i>NLRP3</i>, <i>ICAM1</i>, <i>SIRT1</i>, Notch ligands <i>JAG1</i> and <i>DLL4,</i> and <i>HES1</i>, a Notch target gene. We found that 1-month treatment with ticagrelor, but not clopidogrel, led to increased levels of <i>SIRT1</i> and <i>HES1</i> mRNAs. In patients treated with ticagrelor or clopidogrel, we observed a negative correlation among changes in both <i>SIRT1</i> and <i>HES1</i> mRNA and serum levels of Epidermal Growth Factor (EGF), a marker of endothelial dysfunction found to be reduced by ticagrelor treatment in our previous study. In conclusion, we report that in stable CAD/COPD patients ticagrelor positively regulates <i>HES1</i> and <i>SIRT1</i>, two genes playing a protective role in the context of inflammation and oxidative stress. Our observations confirm and expand previous studies showing that the beneficial effects of ticagrelor in stable CAD/COPD patients may be, at least in part, mediated by its capacity to reduce systemic inflammation and oxidative stress.